Prosecution Insights
Prosecution Insights
17 pending office actions • 10 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (12%) |
| §103 only | 6 (35%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 2 (12%) |
| Multi-statute (no §101) | 5 (29%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRABER, JAMES J | 2 | 45.9% | +57.0% |
| WANG, RUIXUE | 1 | 57.4% | +22.1% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| LEITH, NANCY J | 1 | 74.7% | +43.8% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.3% |
| LEONARD, ARTHUR S | 1 | 50.9% | +50.5% |
| SUNSHINE, HANNAH LOUISE | 1 | 67.7% | +14.1% |
| RIGA, MICHAEL ANGELO | 1 | 56.7% | +59.7% |
| WHITE, ASHLEY TAYLOR | 1 | 26.3% | +45.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | LANDSMAN, ROBERT S | 24d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779841 | USE OF PROTEASE SERINE 21 (PRSS21) ANTIGEN TESTING IN THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA | SALMON, KATHERINE D | 11d overdue |
| 17918644 | CHIMERIC MYD88 RECEPTORS | SUNSHINE, HANNAH LOUISE | 34d |
| 16467358 | DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY | MOSS, NATALIE M | 70d |
| 18681966 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | WANG, RUIXUE | — |
| 18272536 | Systems and Methods for Base Editing Of HBG1/2 Gene Promoter and Fetal Hemoglobin Induction | LEITH, NANCY J | — |
| 17801907 | RECOMBINANT FIBCD1 AND USE THEROF IN THE TREATMENT OF MUSCLE ATROPHY | WHITE, ASHLEY TAYLOR | — |
| 17605639 | GENE KNOCK-OUTS TO IMPROVE T CELL FUNCTION | ABBOTT, KODYE LEE | — |
| 17819810 | TUMOR SUPPRESSION BY MODULATION OF NON-CANONICAL AUTOPHAGY (LAP) IN MYELOID CELLS | GAO, ASHLEY HARTMAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917198 | B7-H3 CHIMERIC ANTIGEN RECEPTORS | RIGA, MICHAEL ANGELO | 72d overdue |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | LANDSMAN, ROBERT S | 24d overdue |
| 18541691 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | VALENROD, YEVGENY | 11d overdue |
| 17918644 | CHIMERIC MYD88 RECEPTORS | SUNSHINE, HANNAH LOUISE | 34d |
| 17258533 | USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS | GRABER, JAMES J | 79d |
| 18681966 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | WANG, RUIXUE | — |
| 18272536 | Systems and Methods for Base Editing Of HBG1/2 Gene Promoter and Fetal Hemoglobin Induction | LEITH, NANCY J | — |
| 18257680 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1628 | 2 |
| 1647 | 2 |
| 1634 | 2 |
| 1653 | 2 |
| 1636 | 1 |
| 1638 | 1 |
| 1678 | 1 |
| 1687 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681966 | METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION | WANG, RUIXUE | — | §102§103§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18541691 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | VALENROD, YEVGENY | 1628 | §112Other | Final Rejection | 11d overdue | Pending | Dec 15, 2023 |
| 18272536 | Systems and Methods for Base Editing Of HBG1/2 Gene Promoter and Fetal Hemoglobin Induction | LEITH, NANCY J | 1636 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18257680 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | CORNET, JEAN P | 1628 | §103§112DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | LANDSMAN, ROBERT S | 1647 | §103 | Final Rejection | 24d overdue | Pending | Mar 14, 2023 |
| 18003093 | METHODS OF GENERATING AN ACTIVATION INDUCIBLE EXPRESSION SYSTEM IN IMMUNE CELLS | LEONARD, ARTHUR S | 1631 | §103 | Final Rejection | — | Pending | Dec 22, 2022 |
| 17918644 | CHIMERIC MYD88 RECEPTORS | SUNSHINE, HANNAH LOUISE | 1647 | §102§103§112Other | Final Rejection | 34d | Pending | Oct 13, 2022 |
| 17917198 | B7-H3 CHIMERIC ANTIGEN RECEPTORS | RIGA, MICHAEL ANGELO | 1634 | §103 | Final Rejection | 72d overdue | Pending | Oct 05, 2022 |
| 17801907 | RECOMBINANT FIBCD1 AND USE THEROF IN THE TREATMENT OF MUSCLE ATROPHY | WHITE, ASHLEY TAYLOR | 1653 | §103 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17783040 | Method for Preparing CD7-Negative, CD3-Positive T Cells | GRABER, JAMES J | 1631 | §103DPOther | Non-Final OA | — | Pending | Jun 07, 2022 |
| 17550051 | Use of FOXP3 Enhancers to Modulate Regulatory T Cells | WILSON, MICHAEL C | 1638 | — | Final Rejection | 2d overdue | Pending | Dec 14, 2021 |
| 17605639 | GENE KNOCK-OUTS TO IMPROVE T CELL FUNCTION | ABBOTT, KODYE LEE | 1634 | §102§103§112Other | Final Rejection | — | Pending | Oct 22, 2021 |
| 17819810 | TUMOR SUPPRESSION BY MODULATION OF NON-CANONICAL AUTOPHAGY (LAP) IN MYELOID CELLS | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Final Rejection | — | Pending | Aug 15, 2022 |
| 17792284 | ERROR SUPPRESSION IN GENETIC SEQUENCING | THOMPSON, MILANA KAYE | 1687 | §103 | Final Rejection | — | Pending | Jul 12, 2022 |
| 17779841 | USE OF PROTEASE SERINE 21 (PRSS21) ANTIGEN TESTING IN THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA | SALMON, KATHERINE D | 1682 | §102§103§112 | Non-Final OA | 11d overdue | Pending | May 25, 2022 |
| 17258533 | USE OF IL-12 TO ALTER EPIGENETIC EFFECTOR PROGRAMS IN CD8 T CELLS | GRABER, JAMES J | 1631 | §103Other | Final Rejection | 79d | Pending | Jan 07, 2021 |
| 16467358 | DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY | MOSS, NATALIE M | 1653 | §101§103 | Non-Final OA | 70d | Pending | Jun 06, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial